Additional Study Information: The purpose of this study is to determine the effectiveness and safety of the study drug moxetumomab pasudotox in treating children with relapsed or refractory pALL or Lymphoblastic Lymphoma of B-cell origin. Moxetumomab pasudotox is made up of two parts: 1) a modified mouse antibody that attaches to a protein from the immune system, called CD22, which can be found on the surface of cancer cells, and 2) a toxin (a type of poison). An antibody is a type of protein that your/your childs immune system makes when it sees a foreign substance in your/your childs body. The modified mouse antibody used in moxetumomab pasudotox has been changed in the laboratory to contain only the part that attaches to CD22. The second part of moxetumomab pasudotox is a toxin that is made by bacteria. Moxetumomab pasudotox is made by combining the portion of the antibody that attaches to CD22 with the toxin. Inlaboratory experiments, moxetumomab pasudotox has been shown to kill leukemia cells that have the CD22 protein on their surface and to decrease tumors in mice. We hope this study will show that moxetumomab pasudotox can work in humans to kill cancer cells especially those cells that have CD22 on their surface.